Massimo Federico - EMA

Transcript

Curriculum Vitae
PERSONAL INFORMATION
Massimo Federico
WORK EXPERIENCE
May 2005–Present
Director, Medical Oncology
University of Modena and Reggio Emilia, (Italy)
Director of the Medical Oncology and Lymphoma Unit at Modena Cancer Center, Modena, Italy, as
well as Director of the Modena Cancer Registry (Registro Tumori di Modena) and President of the
Angela Serra Association for Cancer Research (Associazione Angela Serra per la ricerca sul cancro).
Related document(s):
EDUCATION AND TRAINING
May 2005–Present
Professor of Medical Oncology
University of Modena and Reggio Emilia, (Italy)
Professor Federico graduated from medical school in 1974 and was then faced with the decision of
choosing a subspeciality. He selected a 3-year hematology post-graduate course at the University of
Modena and, after it concluded in 1977 undertook a 5-year program on internal medicine at the
University of Pavia. Dr Federico is board-certified in hematology and internal medicine. After working
in the department of internal medicine in Modena, he moved to the new area of medical oncology.
Professor Federico is now Professor of Medical Oncology at the University of Modena and Reggio
Emilia, Modena, Italy, and Director of the Medical Oncology and Lymphoma Unit at Modena Cancer
Center, Modena, Italy, as well as Director of the Modena Cancer Registry (Registro Tumori di
Modena)
Related document(s):
ADDITIONAL INFORMATION
Expertise
Prof. Federico has a board range of transational scientific and clinical interests, spanning cancer
epidemiology, hereditary breast cancer, design and conduction of clinical trials, and clinical
management of lymphomas (including Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, and hairy cell
leukemia) and breast cancer. He has published in all of this area as author or co-author of over 400
articles (more than 280 on PubMed), most of them in peer-reviewed journals. As a Director of Modena
Cancer Registry has published several Monographies on cancer epidemiology in the Province of
Modena for the years 1988-2011.
Professor Federico’s clinical research career began during the postgraduate hematology program in
Modena. In 1976 he first joined the team to investigate the role of allogenic stem cell transplantation in
homozygous twins.
In 1988 and the in 1989, Professor Federico went to the US as Visiting Research Associate at the
Department of Electrical and Computer Engineering, Bioacustic Research Laboratory of the University
of Illinois (Urbana, Illinois). He worked in basic research with a group of biophysicists involved in
research on improving the role of bone marrow imaging then MRI.
In 1993, Professor Federico went to the US for his second sabbatical as Visiting Research Associate,
this time at the Arizona Cancer Center of the University of Arizona, Tucson. His work was split
between the development of smarter strategies and designs for controlled clinical trials, better analysis
of clinical data, expertise in biostatistics and data analysis and interpretation, and investigating the role
of in vitro testing of new drugs for advanced ovarian cancer, an area of specialized research for the
Center. Back in Italy in December 1995, he continued his work on lymphoma research in Modena.
Currently he is spending a third sabbatical as visiting professor at University of Salento, Lecce,
promoting the growth of an area of excellence in the field of clinical research at UNISALENTO.
The most important work done by Professor Federico in the last 20 years was investigating prognostic
factors in different lymphomas, including Hodgkin Lymphoma (HL), follicular lymphoma (FL),
Peripheral T Cell Lymphoma (PTCL), and Splenic Marginal Zone Lymphoma (SMZL) . At the
24/5/14
© European Union, 2002-2014 | http://europass.cedefop.europa.eu
Page 1 / 20
Curriculum Vitae
Massimo Federico
beginning, the most relevant contribution was investigating the prognosis of HL, then moving to FL,
SMZL, and eventually PTCL, with the aim to help in choosing more appropriate treatments for affected
patients.
He has conducted several phase II and III clinical trials comparing different treatment strategies for HL,
DLBCL, Indolent lymphoma, and FL.
Publications
14) Gobbi P.G., Cavalli P., Franzini B., Di Prisco A.U., Federico M., Bonacorsi G.: Tonsillectomy: a
prognostic factor in Hodgkin’s disease?
Tumori 67:425-430, 1981.
19) Artusi T., Saragoni A., Bonacorsi G., Di Prisco A.U., Spedicato M., Silingardi V., Federico M.:
Castleman’s lymphoadenopathy: twenty years of observation. I. General considerations.
Monoadenopathic variety.
Haematologica 67:109-123, 1982.
20) Artusi T., Bonacorsi G., Saragoni A., Spedicato M., Rinaldi G., Federico M., Silingardi V.:
Castleman’s lymphoadenopathy. II. Generalized form.
26) Gobbi P.G., Attardo Parrinello G., Di Prisco A.U., Federico M., Bonacorsi G., Dini D., Marabelli S.,
Rizzo S.C., Ascari E.: New clinical criteria for the assessment of liver involvement in Hodgkin’s
disease.
Eur. J. Cancer Clin. Oncol. 18:1243-1249, 1982.
40) Federico M., Barbieri F., Dini D., Bonacorsi G., Fontana G., Rinaldi G., Artusi T., Silingardi V.: A
report of seven long survivors for evidence of prognostic factors in hairy cell leukemia.
Tumori 70:518-521, 1984.
41) Gobbi PG., Gendarini A., Crema A., Cavalli C., Attardo Parrinello G., Federico M., Di Prisco AU.,
Ascari E. Serum albumin in Hodgkin’s disease.
Cancer 55:389-93, 1985.
50) Gobbi PG., Cavalli C., Gendarini A., Crema A., Ricevuti G., Federico M., Di Prisco AU., Ascari E.:
Reevaluation of prognostic significance of symptoms in Hodgkin’s disease.
Cancer 56:2874-2880, 1985.
51) Silingardi V., Federico M., Barbieri F., Artusi T., Mauri C.: Hairy cell leukemia: a reversible disease?
A report of two cases of spontaneous remission.
67) Damasio EE., Bernasconi C., Castoldi GL., Chisesi T., Federico M., Lamparelli T., Lauria F.,
Pagnucco G., Resegotti L., Rossi E.: Human Lymphoblastoid interferon for HCL: results from the
Italian Cooperative Group.
Leukemia 1:331-33, 1987.
76) Gobbi GP., Cavalli C., Federico M., Bertoloni D., Di Prisco AU., Rossi A., Silingardi V., Mauri C.,
Ascari A.: Hodgkin’s disease prognosis: a directly predictive equation.
Lancet 675-679, 1988.
90) Silingardi V., Davolio Marani S., Federico M., Piccinini L., Frassoldati A., Sarti M., Burani A.,
Canossi GC.: Bone marrow infiltration in Hairy cell leukemia after Interferon therapy detected by
magnetic resonance imaging.
Eur. J. Cancer Clin. Oncol., 25:209-213, 1989.
92) Gobbi GP., Cavalli C., Federico M., Lombardo M., Bertoloni D., Grignani GE., Pieresca C., Ascari
A., Mauri C.: Increasing interdependency of prognosis and therapy-related factors in Hodgkin’s
disease.
Acta Haematol. 81:34-40, 1989.
101) Damasio E.E., Pagnucco G., Federico M., Annino L., Chisesi T., Lamparelli T., Lauria F., Castoldi
GL., Resegotti L.: Hairy Cell Leukemia. A therapeutical update.
102) Federico M., Iannone A., Chan H.C., Magin RL.: Bone Marrow Uptake of Liposome-Entrapped
Spin Label after Liver Blockade with Empty Liposomes.
Magnetic Resonance in Medicine. 10:418-425, 1989.
24/5/14
Page 2 / 20
Curriculum Vitae
Massimo Federico
104) Federico M., Chisesi T., Lauria F., Bernasconi C., Capnist G., Castoldi G., Damasio EE.,
Pagnucco G., Frassoldati A., Resegotti L., Silingardi V.: Human Lymphoblastoid interferon as initial
therapy in hairy cell leukemia: a multicenter study in non-splenectomized patients.
Brit. J. Haematol., 72:54-56, 1989.
105) Federico M., Magin RL., Swartz HM., Wright RM., Silingardi V.: Detection of bone marrow
involvement in patients with cancer.
Tumori, 75:90-96, 1989.
125) Silingardi V., Federico M., Frassoldati A., Barbieri F., Palomba G., Mauri C.: Free from failure
survival in Hodgkin’s disease. Long term analysis of 148 cases treated with a MOPP modified
protocol.
Acta Haematol. 82:179-186, 1989.
126) Federico M., Gobbi PG., Barbieri F., Silingardi V. Relationship between prognostic factors and
therapy in high grade non Hodgkin’s lymphomas over two decades.
153) Ferrari P., Federico M., Grimaldi L.M.E., Silingardi V.: Stiff-man syndrome in a patient with
Hodgkin’s disease. An unusual paraneoplastic syndrome.
Haematologica, 75:570-572, 1990.
164) Torelli G., Marasca R., Luppi M., Selleri L., Ferrari M., Narni F., Mariano M.T., Federico M.,
Ceccherini Nelli L., Bendinelli M., Montagnani G., Montorsi M., Artusi T.: Human Herpes Virus-6 in
human lymphomas: identification of specific sequences in Hodgkin’s lymphomas by Polimerase Chain
Reaction.
Blood 77:1-5, 1991.
166) Capnist G., Federico M., Chisesi T., Resegotti L., Pagnucco G., Castoldi G.L., Lamparelli T.,
Frassoldati A., Guarnaccia C., Leoni P., Fabris P., Rossi G., Invernizzi R., Ambrosetti A., Bernasconi
C., Damasio E.: Should alpha interferon be used as primary treatmant for Hairy Cell Leukemia?
Leukemia Research 15:419-426, 1991.
176) Iannone A., Magin R.L., Walczac T., Federico M., Swartz H.M., Tomasi A., Vannini V.: Blood
clearance of dextran magnetite particles by a noninvasive in vivo ESR method.
Magnetic Resonance in Medicine 22:435-442, 1991.
186) Cirillo M., Federico M., Curci G., Tamborrino E., Piccinini L., Silingardi V.: Primary gastro intestinal
lymphoma: a clinico pathologic study of 58 cases.
192) Iannone A., Federico M., Tomasi A., Magin R.L., Casasco A., Calligaro A., Vannini V.: Detection
and quantitation in rat tissues of the superparamagnetic MR contrast agent Dextran Magnetite as
demonstrated by ESR spectroscopy.
Investigative Radiology 27:450-455, 1992.
205) Gobbi P.G., Pieresca C., Federico M., Di Renzo N., Narni F., Iannitto V., Grignani G., Cavanna L.,
Avanzini P., Partesotti G., Pitini V., Ascari E., Silingardi V., Mauri C.: MOPP/EBV/CAD hybrid
chemotherapy + limited radiotherapy in advanced or unfavorably presenting Hodgkin’s disease.
J. Clin. Oncol. 11:712-719, 1993.
213) Brugiatelli M., Federico M., Gobbi P.G., Avanzini P., Callea V., Cavanna L., De Pasquale A., Di
Prisco A.U., Di Renzo N., Silingardi V., Mauri C.: Epidoxorubicin vs Idarubicin containing regimens in
intermediate and high grade non Hodgkin’s lymphoma: preliminary results of a multicentric
randomized trial.
222) Frassoldati A., Lamparelli T., Federico M., Annino L., Capnist G., Pagnucco G., Resegotti L.,
Damasio E.E.: Hairy cell leukemia. A clinical review based on 725 cases of the italian cooperative
group.
Leukemia & Lymphoma 13:307-316, 1994. Guarnaccia C., Leoni P., Lauria F., Pagnucco G.,
Frassoldati A., Damasio E.: Long term results of interferon treatment in hairy cell leukemia.
Leukemia and Lymphoma 14:457-464, 1994.
223) Capnist G., Federico M., Chisesi T., Resegotti L., Lamparelli T., Fabris P., Rossi G., Invernizzi R.,
Guarnaccia C., Leoni P., Lauria F., Pagnucco G., Frassoldati A., Damasio E.: Long term results of
interferon treatment in hairy cell leukemia.
24/5/14
Page 3 / 20
Curriculum Vitae
Massimo Federico
Leukemia & Lymphoma (ISSN 1042-8194) 14-457:464, 1994
224) Federico M., Frassoldati A., Lamparelli T., Foa’ R., Brugiatelli M., Annino L., Baldini L, Capnist G.,
Chisesi T., Francia di Celle P., Invernizzi R., Lauria F., Truini M., Resegotti L., Silingardi V., Damasio
E.E. for the ICGHCL: Long term results of alpha interferon as initial therapy and splenectomy as
consolidation therapy in patients with hairy cell leukemia. Final report from the Italian cooperative
group for HCL
Annals of Oncology, 5:725-731, 1994.
233) Silingardi V., Federico M., Cavanna L., Avanzini P., Gobbi P.G., Lombardo M., Carotenuto M.,
Frassoldati M., Pieresca C., Vallisa D., Merli F., Ascari E., Mauri M.: ProMECE-CytaBOM vs MACOPB in advanced aggressive non-Hodgkin’s lymphoma. Long-term results of a multicenter study of the
Italian lymphoma study group (GISL).
Leukemia and Lymphoma 17:313-320, 1995.
257) Sabbatini R., Federico M., Baldini L., Maiolo M.T., Silingardi V.: A randomised double-blind,
cross-over study comparing levosulpiride-based with metoclopramide-based combination in the
prevention of ProMECE-CytaBOM induced emesis.
Haematologica, 80:416-420, 1995.
258) Longo G., Federico M., Pieresca C., Avanzini P., Iannitto E., Di Prisco A.U., Baldini L., Brugiatelli
M., Clò V., Bevini M., Silingardi V.: Anaplastic large cell lymphoma. Analysis of 35 cases followed at
GISL centers.
Eur. J. Cancer, 31:1763-1767, 1995.
262) Gobbi P.G., Pieresca C., Frassoldati A., Carotenuto M., Di Renzo N., La Sala A., Bertè R.,
Federico M., Silingardi V., Ascari E. Vinblastine, bleomycin and methotrexate (VBM) chemotherapy
plus extended field radiotherapy in early, favourably presenting, clinically staged Hodgkin’s patients:
The gruppo Italiano per lo Studio dei Linfomi Experience
J. Clin. Oncol, 14:527-533, 1996
263) Carella AM, Prencipe E, Pungolino E, Lerma E, Frassoni F, Rossi E, Giordano D, Occhini D,
Gatti AM, Bruni R, Spriano M, Nati S, Pierluigi D, Congiu M, Vimercati R, Rovatti JL, Federico M.
Twelve years experience with high dose therapy and autologous stem cell transplantation for high risk
Hodgkin’s disease patients in first remission after MOPP/ABVD.
Leukemia & Lymphoma 21:63-70, 1996.
274) Luppi M., Morselli M., Bandieri E., Federico M., Marasca R., Barozzi P., Ferrari M.G., Savarino
M., Torelli G.: Sensitive detection of circulating breast cancer cells by reverse-transcriptase
polymerase chain reaction of maspin gene.
Ann. Oncol. 7:619-624,1996
279) Gobbi P.G., Pieresca C., Cavanna L., Corbella F., Vallisa D., Federico M., Formisano R.,
Carotenuto M., Merli F., Callea V., Angrilli F., Silingardi V.:CCNU, Vinblastine, Procarbazine and
Prednisone (CVPP) with extended-field radiotherapy in the treatment of early unfavorable Hodgking’s
disease. A prospective study on behalf of the Gruppo Italiano per lo Studio dei Linfomi (GISL).
Haematologica, 81: 503-512, 1996
286) Baldini L., Guffanti A., Gobbi P., Colombi M., Federico M., Avanzini P., Cavanna L., Pieresca C.,
Silingardi V., Maiolo A.T. for the Gruppo Italiano per lo Studio dei Linfomi (GISL): A pilot study on use
of PROMACE-CYTABOM regimen as first line treatment in advanced follicular lymphoma.
Cancer 79:1234-1240,1997
302) Iannitto E., Accurso V., Federico M., Vallisa D., Pieresca C., Gravina S.F., Di Costanzo F., Di
Trapani R., Silingardi V., Mariani G.: Hodgkin’s disease presentig below the diaphragm. The
experience of the Gruppo Italiano Studio Linfomi (GISL).
Haematologica 82: 676-682, 1997.
309) Merli F., Federico M., Avanzini P., Ilariucci F., Stelitano C., Iannitto E., Colombi M., Vallisa D.,
Santagati G., Piccinini L.: Weekly administration of vincristine, cyclophosphamide, mitoxantrone and
bleomycin (VEMB) in the treatment of elderly aggressive non Hodgkin's lymphoma.
Haematologica 83:217-221, 1998
310) Gobbi P.G., Pieresca C., Ghirardelli M.L., Di Renzo N., Federico M., Merli F., Iannitto E., Pitini V.,
Grignani G., Donelli A., Carotenuto M., Silingardi V., and Ascari E. for the Gruppo Italiano per lo Studio
dei Linfomi: Long-term results from MOPPEBVCAD chemotherapy with optional limited radiotherapy
in advanced Hodgkin's disease.
Blood 91(8):2704-2712, 1998.
24/5/14
Page 4 / 20
Curriculum Vitae
Massimo Federico
322) Federico M., Clo' V., Brugiatelli M., Carotenuto M., Gobbi PG., Vallisa D., Lombardo M., Avanzini
P., Di Renzo N., Dini D., Baldini L., Ginaldi L., Silingardi V., Mauri C.: Efficacy of two different
ProMACE-CytaBOM derived regimens in Advanced Aggressive Non Hodgkin's Lymphoma. Final
report of a multicenter trial conducted by GISL.
Haematologica,83:800-811,1998
328) Federico M., Maiorana A., Mangone L., Turchetti D., Canossi B., Cortesi L., Romagnoli R.,
Silingardi V.: Identification of families with hereditary breast and ovarian cancer for clinical and
mammographic surveillance. The Modena Study Group proposal.
Breast Cancer Research and Treatment 55:213-221, 1999.
330) Longo G., Fiorani C., Sacchi S., Callea V., Lombardo M., Federico M., Stelitano C., Angrilli F.,
Vallisa D., Gobbi P.G., Ilariucci F., Frassoldati A., Petrini M., Silingardi V. for the Gruppo Italiano per lo
Studio dei Linfomi (GISL): Clinical characteristics, treatment outcome and survival of 36 adult patients
with primary anaplastic large cell lymphoma.
359) Cortesi L., Turchetti D., Bertoni C., Bellei R., Mangone L., Vincenti M., Federico M., Silingardi V.,
Ferrari S.: Comparison between genotype and phenotype identifies a high-risk population carrying
BRCA I mutation.
Genes, Chromosomes and Cancer, 27:130-135, 2000.
360) Federico M., Vitolo U., Zinzani P.L., Chisesi T., Clò V., Bellesi G., Magagnoli M., Liberati M.,
Boccomini C., Niscola P., Pavone V., Cuneo A., Santini G., Brugiatelli M., Baldini L., Rigacci L.,
Resegotti L. for the Intergruppo Italiano Linfomi: The prognosis of follicular lymphoma: a predictive
model based on a retrospective analysis of 987 cases of the Italian Lymphoma Intergroup.
Blood, 95:3,783-789, 2000.
361) Stelitano C., Baldini L., Pieresca C., Callea V., Angrilli F., Clo V., Partesotti G., Merli F., Cavanna
L., Morabito F., Federico M., Brugiatelli M., Silingardi V.: Validation of the international prognostic index
in working formulation group a low-grade non-Hodgkin’s lymphoma: retrospective analysis of 137
patients from the Gruppo Italiano per lo studio dei linfomi registry.
Haematologica, 85:2,154-159, 2000.
375) Sabbatini R., Federico M., Depenni R., Morselli M., Cagossi K., Luppi M., Torelli G., Silingardi V.:
Detection of circulating tumor cells in patients with breast cancer undergoing conventional-dose
chemotherapy by RT-PCR of Maspin.
Journal of Clinical Oncology, 18:9,1914-1920,2000.
379) Turchetti D., Cortesi L., Federico M., Bertoni C., Mangone L., Ferrari S., Silingardi V.: BRCA1
Mutations and clinicopathological features in a sample of italian women with early-onset breast
cancer.
European Journal of Cancer, 36-1-6:2083-2089,2000. 392) Sacchi S., Federico M., Dastoli G., Fiorani
C., Vinci G., Clò V., Casolari B.: Treatment of B-cell low-grade non-Hodgkin’s lymphoma with anti CD
20 monoclonal antibody Rituximab.
Critical Reviews in Oncology-Hematology, 37:13-25,2001.
392) Sacchi S., Federico M., Dastoli G., Fiorani C., Vinci G., Clò V., Casolari B.: Treatment of B-cell
low-grade non-Hodgkin’s lymphoma with anti CD 20 monoclonal antibody RituximabCritical Reviews
in Oncology-Hematology (ISSN 1040-8428) 37-13:25, 2001
395) Gobbi P.G., Zinzani P.L., Broglia C., Comelli M., Magagnoli M., Federico M., Merli F., Iannitto E.,
Tura S., Ascari E.: Comparison of prognostic models in patients with advanced Hodgkin disease.
(Promising results from integration of the Best Three Systems).
Cancer, 91:8,1467-1478,2001.
400) Guglielmi C., Martelli M., Federico M., Zinzani P.L., Vitolo U., Bellesi G., Santini G., Tarella C.,
Zallio F., Pregno P., Di Renzo N., Resegotti L.: Risk assessment in diffuse large cell lymphoma at first
relapse. A study by the Italian Intergroup for Lymphomas.
Haematologica 86:9,941-950, 2001
402) Sacchi S., Federico M., Vitolo U., Boccomini C., Vallisa D., Baldini L., Petrini M., Rupoli S., Di
Raimondo F., Merli F., Liso V., Tabilio A., Saglio G., Vinci G., Brugiatelli M., Dastoli G. for GISL: Clinical
activity and safety of combination immunotherapy with interferon-2a and rituximab in patients with
relapsed low grade non-Hodgkin’s lymphoma.
Haematologica 86:99,951-958,2001
426) Federico M., Zinzani P.L., Frassoldati A., Vinceti M., Modè A., Annino L., Chisesi T., Pagnucco
24/5/14
Page 5 / 20
Curriculum Vitae
Massimo Federico
G., Invernizzi R., Spriano M., Resegotti L., Bendandi M., Damasio E. for the Italian Cooperative Group
for the Study of Hairy Cell leukemia: Risk of second cancer in patients with hairy cell leukemia: longterm follow up.
Journal of Clinical Oncology 20:39,638-646, 2002.
427) Chisesi T., Federico M., Levis A., Lambertenghi Deliliers G., Gobbi P.G., Santini G., Luminari S.,
Brugiatelli M.: ABVD versus Stanford V versus MEC in unfavourable Hodgkin’s lymphoma: results of a
randomised trial. Fifth International Symposium on Hodgkin’s Lymphoma, Cologne, Germany, 22-25
September 2002.
Annals of Oncology 13:19,102-106, 2002.
428) Del Rio G., Zironi S., Valeriani L., Menozzi R., Bondi M., Bertolini M., Piccinini L., Banzi M.C.,
Federico M.: Weight gain in women with breast cancer treated with adjuvant Cyclophosphamide,
Methotrexate and 5-Fluorouracil. Analysis of resting energy expenditure and body composition.
Breast Cancer Research and Treatment 73:267-273, 2002.
429) Turchetti D., Mangone L., Negri R., Rossi G., Cortesi L., Vinceti M., Maiorana A., Gallo E.,
Federico M.:Changes in breast cancer incidence and stage distribution in Modena, Italy: the effect of a
mammographic screening program.
Cancer Causes and Control, 13:729-734, 2002.
433) Morabito F., Baldini L., Stelitano C., Luminari S., Frassoldati A., Merli F., Colombi M., Sabbatini
R., Brugiatelli M., Federico M., for the Gruppo Italiano per lo Studio dei Linfomi (GISL): Prospective
study of indolent non-follicular non-Hodgkin’s lymphoma: validation of Gruppo Italiano per lo Studio dei
Linfomi (GISL) prognostic criteria for watch and wait policy.
Leukemia and Lymphoma, 43:10,1933-1938, 2002
443) Lombardo M., Morabito F., Merli F., Molica S., Cavanna L., Sacchi S., Broglia C., Angrilli F.,
Ilariucci F.,
Stelitano C., Luisi D., Berte’ R., Luminari S., Federico M., Brugiatelli M. for GISL:
Bleomycin,Epidoxorubicin, Cyclophosphamide, Vincristine and Prednisone (BACOP) in patients with
follicular non-Hodgkin’s lymphoma: results of a prospective, multicenter study of the Gruppo Italiano
per lo Studio dei Linfomi (GISL).
Leukemia and Lymphoma, 43:9,1795-1801, 2002.
444) Galimberti S., Marasca R., Caracciolo F., Fazzi R., Papineschi F., Benedetti E., Guerrini F.,
Morabito F., Oliva E., Di Renzo N., Federico M., Petrini M., Torelli G. for GISL: The role of molecular
monitoring in autotransplantation for non-Hodgkin’s lymphoma.
Bone Marrow Transplantation, 29:581-587, 2002.
445) Zinzani P.L., Martelli M., Bertini M., Gianni A.M., Devizzi L., Federico M., Pangalis G., Michels J.,
Zucca E., Cantonetti M., Cortelazzo S., Wotherspoon A., Ferreri A.J.M., Zaja F., Lauria F., De Renzo
A., Liberati M.A., Falini B., Balzarotti M., Calderoni A., Zaccaria A., Gentilini P., Fattori P.P., Pavone E.,
Angelopoulou M.K., Alinari L., Brugiatelli M., Di Renzo N., Bonifazi F., Pileri S.A., Cavalli F. for the
International Extranodal Lymphoma Study Group (IELSG): Induction chemotherapy stategies for
primary mediastinal large B-cell lmphoma with sclerosis: a retrospective multinational study on 426
previously untreated patients.
Haematologica, 87:12,1258-1264, 2002
446) Turchetti D., Cortesi L., Federico M., Romagnoli R., Silingardi V.: Hereditary risk of breast cancer:
not only BRCA.
Journal of Experimental Clinical Cancer Research, 21:3,17-21, 2002
448) Cortesi L., Canossi B., De Santis M., Panizza P., Rossi G., Turchetti D., Del Maschio A., Ferrarri
S., Romagnoli R., Federico M., Silingardi V.: Usefulness of breast MRI in a patient with genetic risk.
Journal of Experimental Clinical Cancer Research, 21:3,131-136, 2002
449) Baldini L., Brugiatelli M., Luminari S., Lombardo M., Merli F., Sacchi S., Gobbi P., Liberati M.,
Cavanna L., Colombi M., Stelitano C., Goldaniga M., Morabito F., Federico M., Silingardi V.: Treatment
of indolent B-cell non-follicular lymphomas: final results of the LL01 randomized trial of the Gruppo
Italiano per lo Studio dei Linfomi (GISL).
Journal of Clinical Oncology, 21:8,1459-1465,2003
460) Cortesi L., Turchetti D., Bertoni C., Zanocco-Marani T., Vinceti M., Silvestri C., Federico M.,
Silingardi V. and Ferrari S.: Italian family with two independent mutations: 3358T/A in BRCA1 and
8756delA in BRCA2 genes.
European Journal of Human Genetics 11: 210-214, 2003
24/5/14
Page 6 / 20
Curriculum Vitae
Massimo Federico
462) Luminari S., Goldaniga M., Ceccherelli F., Guffanti A., Bombardieri E., Marcheselli R., Cro L.,
Colombi M., Federico M. and Baldini L.: Prevalence and prognostic significance of sMUC-1 levels in
plasma cell dyscrasias.
British Journal of Haematology 121:772-774, 2003
463) Federico M., Bellei M., Brice P., Brugiatelli M., Nagler A., Gisselbrecht C., Moretti L., Colombat
Ph., Luminari S., Fabbiano F., Di Renzo N., Goldstone A., Carella A.M., on behalf of participants of
EBMT/GISL/ANZLG/SFGM/GELA Intergroup HD01 Trial: High dose therapy and autologous stem cell
transplantation versus conventional therapy for patients with advanced Hodgkin’s Lymphoma
responding front line therapy.
Journal of Clinical Oncology, 21:12,2320-2325, 2003
464) Buiatti E., Barchielli A., Bartolacci S., Federico M., De Lisi V., Bucchi L., Ferretti S., Paci E.,
Segnan N., Tumino R. and the SCREENREG Working Group: The impact of organised Screening
programmes on the stage-specific incidence of breast cancer in some Italian areas.
Europen Journal of Cancer 39:1776-1782, 2003
465) Aretini P., D’Andrea E., Pasini B., Viel A., Mariani Costantini R., Cortesi L., Ricevuto E., Agata S.,
Bisegna R., Boiocchi M., Caligo M.A., Chieco-Bianchi L., Cipollini G., Crucianelli R., D’Amico C.,
Federico M., Ghimenti C., De Giacomi C., De Nicolo A., Della Puppa L., Ferrari S., Ficorella C.,
Iandolo D., Manoukian S., Marchetti P., Marroni F., Menin C., Montagna M., Ottini L., Pensotti V.,
Pierotti M., Radice P., Santarosa M., Silingardi V., Turchetti D., Bevilacqua G. and Presciuttini S.:
Different expressivity of BRCA1 and BRCA2: analysis of 179 Italian pedrigees with identified mutation.
Breast Cancer Research and Treatment, 81:71-79, 2003
466) Franceschi S., Dal Maso L., Pezzotti P., Polesel J., Braga C., Piselli P., Serraino D., Tagliabue G.,
Federico M., Ferretti S., De Lisi V., La Rosa F., Conti E., Budroni M., Vicario G., Piffer S., Pannelli F.,
Giacomin A., Bellù F., Tumino R., Fusco M., Rezza G. for the Cancer and AIDS Registry Linkage
Study: Incidence of AIDS-Defining cancers after AIDS Diagnosis among people with AIDS in Italy,
1986-1998
J Acquir Immune Defic Syndr, 34-1:84-90, 2003
469) Luminari S., Casolo A., De Santis M., Federico M.: Images in haematology, splenosis peritonei
British Journal of Haematology, 123:378-378, 2003
470) Luminari S., Federico M., Baldini L.: Serum Muc-1 as a marker of disease status in multiple
myeloma patients receiving Thalidomide – response to Mileshkin et al.
British Journal of Haematology, 123:748-748, 2003
471) Gobbi P.G., Broglia C., Merli F., Dell’Olio M., Stelitano C., Iannitto E., Federico M., Luisi D., Molica
S., Cavalli C., Dezza L., Ascari E.: Vinblastine, Bleomycin and Methotrexate chemotherapy plus
irradiation for patients with early-stage, favorable Hodgkin lymphoma: the experience of the Gruppo
Italiano Studio Linfomi.
Cancer, 98-11:2393-401, 2003
472) Tarella C., Cuttica A., Vitolo U., Liberati M., Di Nicola M., Cortelazzo S., Rosato R., Rosanelli C.,
Di Renzo N., Musso M., Pavone E., Santini G., Pescarollo A., De Crescenzo A., Federico M.,
Gallamini A., Pregno P., Romano R., Coser P., Gallo E., Boccadoro M., Barbui T., Pileri A., Gianni
A.M. and Levis A.: High-dose sequential chemotherapy and pheripheral blood progenitor cell (PBPC)
autografting in refractory/relapsed Hodgkin’s limphoma: a multicenter study of Intergruppo Italiano
Linfomi (I.I.L.) showing prolonged disease-free survival in patients treated at first relapse.
Cancer, vol. 98-5: 2748-2759, 2003.
475) Rigacci L., Federico M., Martelli M., Zinzani P.L., Cavanna L., Bellesi G., Merli F., Alterini R.,
Petrucci M.T., Tani M., Liberati A.M., Vitolo U., Pavone V., Cuneo A., Chisesi T., Brugiatelli M.: The role
of anthracyclines in combination chemotherapy for the treatment of follicular lymphoma: retrospective
study of the Intergruppo Italiano Linfomi on 761 cases.
Leukemia and Lymphoma, 44-11:1911-1917, 2003
476) Gallamini A., Stelitano C., Calvi R., Bellei M., Mattei D., Vitolo U., Morabito F., Martelli M.,
Brusamolino E., Iannitto E., Zaja F., Cortelazzo S., Rigacci L., Devizzi L., Todeschini G., Santini G.,
Brugiatelli M., and Federico M. for the Intergruppo Italiano Linfomi: Peripheral T-cell lymphoma
unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study.
Blood, 103-7:2474-2479, 2004
487) Sant M, Allemani C, Berrino F, Coleman MP, Aareleid T, Chaplain G, Coebergh JW, Colonna M,
Crosignani P, Danzon A, Federico M, Gafa L, Grosclaude P, Hedelin G, Mace-Lesech J, Garcia CM,
Moller H, Paci E, Raverdy N, Tretarre B, Williams EM: European Concerted Action on Survival and
24/5/14
Page 7 / 20
Curriculum Vitae
Massimo Federico
Care of Cancer Patients (EUROCARE) WorkingGroup, Breast carcinoma survival in Europe and the
United States.
Cancer, 100:4-715:722, 2004.
490) Contegiacomo A, Pensabene M, Capuano I, Tauchmanova L, Federico M, Turchetti D, Cortesi L,
Marchetti P, Ricevuto E, Cianci G, Venuta S, Barbieri V, Silingardi V.: An oncologist-based model of
cancer genetic counselling for hereditary breast and ovarian cancer.
Ann Oncol.15-5:726-32, may 2004.
491) Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, Au WY, Bellei M,
Brice P, Caballero D, Coiffier B, Conde Garcia E, Doyen C, Federico M, Fisher RI, Garcia-Conde JF,
Guglielmi C, Hagenbeek A, Haioun C, LeBlanc M, Lister AT, Lopez-Guillermo A, Mc Laughlin P,
Milpied N, Morel P, Mounier N, Proctor SJ, Rohatiner A, Smith P, Soubeyran P, Tilly H, Vitolo U,
Zinzani PL, Zucca E, Montserrat E.: Follicular lymphoma international prognostic index.
Blood, 104-5:1258-1265 2004
506) Ferreri A.J.M., Campo E., Ambrosetti A., Ilariucci F., Seymour J.F., Willemze R., Arrigoni G.,
Rossi G., Lopez-Guillermo A., Berti E., Erikson M., Federico M., Cortelazzo S., Govi S., Frungillo N.,
Dell’Oro S., Lestani M., Asioli S., Pedrinis E., Ungari M., Motta T., Rossi R., Artusi T., Iuzzolino P.,
Zucca E., Cavalli F., Ponzoni M., on behalf of the International Extranodal Lymphoma Study Group
(IELSG): Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma.
Annals of Oncology, 15:1215-1221, 2004
509) Merli F., Bertini M., Luminari S., Mozzana R., Bertè R., Trottini M., Stelitano C., Botto B., Pizzuti
M., Quintana G., De Paoli A., Federico M.: Quality of live assessment in elderly patients with
aggressive non-Hodgkin’s lymphoma treated with anthracycline-containing regimens. Report of a
prospective study by the Intergruppo Italiano Linfomi.
Haematologica, 89:973-978, 2004
511) Alemanni C., Sant M., Berrino F., Aareleid T., Chaplain G., Coebergh J.W., Colonna M., Costiero
P., Danzon A., Federico M., Gafà L., Grosclaude P., Hedelin G., Macè-Lesech J., Garcia C.M., Paci
E., Raverdy N., Tretarre B., and EMI Williams: Prognostic value of morphology and hormone receptor
status in breast cancer – a population-based study.
British Journal of Cancer, 91-1263:1268, 2004
515) Morabito F., Gallamini A., Stelitano C., Callea V., Guglielmi C., Neri S., Lazzaro A., Orsucci L.,
Ilariucci F., Sacchi S., Vitolo U. Federico M.: Clinical relevance of immunophenotype in a retrospective
comparative study of 297 peripheral T-cell lymphoma unspecified and 496 diffuse B-cell lymphoma:
the experience of the Intergruppo Italiano Linfoni (studio misto IIL/GISL)
Cancer 101-7:1601-8, 2004
516) Bucchi L., Barchielli A., Ravaioli A., Federico M., De Lisi V., Ferretti S., Paci E., Vettorazzi M.,
Patriarca S., Frigerio A., Buiatti E., and the SCREENREG Working Group: Screen-detected vs clinical
breast cancer: the advantage in the relative risk of lymph node metastases decreases with increasing
tumour size.
517) Dal Maso L., Polesel J., Ascoli V., Zambon P., Budroni M., Ferretti S., Tumino R., Tagliabue G.,
Patriarca S., Federico M., Vercelli M., Giacomin A., Vicario G., Bellù F., Falcini F., Crocetti E., De Lisi
V., Vitarelli S., Piffer S., Stracci F., Serraino D., Rezza G., and Franceschi S., for the Cancer and AIDS
Registry Linkage (CARL) Study: Classic Kaposi’s sarcoma in Italy, 1985-1998
518) Rossi G., Valli R., Bertolini F., Marchioni A., Cavazza A., Mucciarini C., Migaldi M., Federico M.,
Trentini G.P., Sgambato A.: PDGFR expression in differential diagnosis between KIT-negative
gastrointestinal stromal tumours and other primary soft-tissue tumours of the gastrointestinal tract.
Histopathology, 46-522:531, 2005
519) Vitolo U., Liberati A.M., Cabras M.G., Federico M., Angelucci E., Baldini L., Boccomini C.,
Brugiatelli M., Calvi R., Ciccone G., Genua A., Lambertenghi Deliliers G., Levis A., Parvis G., Pavone
E., Salvi F., Sborgia M., Gallo E. on behalf of The Intergruppo Italiano Linfomi: High dose sequential
chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first
line treatment in poor-prognosis diffuse large cell lymphoma: an “Intergruppo Italiano Linfomi”
randomized trial.
Haematologica, 90:6-793:801, 2005
524) Contegiacomo A., Pensabene M., Capuano I., Tauchmanova L., Federico M., Turchetti D.,
Cortesi L., Marchetti P., Ricevuto E., Cianci G., Barbieri V., Venuta S., Silingardi V.: Comment on
24/5/14
Page 8 / 20
Curriculum Vitae
Massimo Federico
“Cancer genetic counselling” by P.Mandich et al. (Ann Oncol 2005, 16-171)
Annals of Oncology, 16:7-1208-1209, 2005
526) Barchielli A., Federico M., De Lisi V., Bucchi L., Ferretti S., Paci E., Ponti., Buiatti E., for the
Screenreg Working Group. In situ breast cancer: incidence trend and organised screening
programmes in Italy.
European Journal of Cancer, 41-7:1045-1050, 2005
527) Gobbi P.G., Levis A., Chisesi T., Broglia C., Vitolo U., Stelitano C., Pavone V., Cavanna L.,
Santini G., Merli F., Liberati M., Baldini L., Lambertenghi Deliliers G., Angelucci E., Bordonaro R.,
Federico M.: ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited
radiotherapy in intermediate–and advanced-stage Hodgkin’s lymphoma: final results of a multicenter
randomized trial by Intergruppo Italiano Linfomi.
Journal of Clinical Oncology, 23-36:9198-9207, 2005
528) Cortesi L., Chiuri V.E., Ruscelli S., Bellelli V., Negri R., Rashid I., Cirilli C., Fracca A., Gallo E.,
Federico M.: Prognosis of screen-detected breast cancer: results of a population based study.
BMC Cancer, 6-17, 2006
529) Morabito F., Stelitano C., Luminari S., Mammi C., Marcheselli L., Callea V., Gentile M., Polimeno
G., Merli F., Molica S., Gobbi P., Angrilli F., Brugiatelli M., Federico M.: The role of high-dose therapy
and autologous stem cell transplantation in patients with primary refractory Hodhkin’s lymphoma: a
report from the Gruppo Italiano per lo Studio dei Linfomi (GISL).
Bone Marrow Transplantation, 37:3-283-288, 2006
530) Federico M., Luminari S., Gobbi P.G., Sacchi S., Di Renzo N., Lombardo M., Merli F., Baldini L.,
Stelitano C., Partesotti G., Polimeno G., Montanini A., Mammi A., Brugiatelli M.: The length of
treatment of aggressive non-Hodgkin’s lymphomas established according to the International
Prognostic Index score: long-term results of the GISL LA03 study.
European Journal of Haematology, 76:3-217-229, 2006
531) Di Renzo N., Brugiatelli M., Montanini A., Vigliotti M.L., Cervetti G., Liberati A.M., Luminari S.,
Spedini P., Giglio G., Federico M.: Vinorelbine, Gemcitabine, Procarbazine and Prednisone (ViGePP)
as salvage therapy in relapsed or refractory aggressive non-Hodgkin’s lymphoma (NHL): results of a
phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi.
Leukemia & Lymphoma, 47-3:473-479, 2006
532) Gobbi P.G., Broglia C., Levis A., La Sala A., Valentino F., Chisesi T., Sacchi S., Corbella F.,
Cavvanna L., Iannitto E., Pavone V., Molica S., Corazza G.R., Federico M.: MOPPEBVCAD
chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin’s lymphoma: 10 year
results, late toxicity and second tumors.
Clinical Cancer Research, 12-2:529-535, 2006
533) Arcaini L., Lazzarino M., Colombo N., Burcheri S., Boveri E., Paulli M., Morra E., Gambacorta M.,
Cortelazzo S., Tucci A., Ungari M., Ambrosetti A., Menestrina F., Orsucci L., Novero D., Pulsoni A.,
Frezzato M., Gaidano G., Vallisa D., Minardi V., Tripodo C., Callea V., Baldini L., Merli F., Federico M.,
Franco V., Iannitto E.: Splenic marginal zone lymphoma: a prognostic model for clinical use.
Blood, 107-12:4643-4649, 2006
534) Gobbi P.G., Broglia C., Valentino F.,Mammi C., Lombardo M., Merli F., Luminari S., Polimeno G.,
Riezzo A., Lambelet P., Rovati A., Corazza G.R., Federico M.: The role of dose size in a
chemotherapy regimen (ProMECE-CytaBOM) for the first-line treatment of large B-cell lymphomas: a
randomized trial by the Gruppo Italiano Studio Linfomi (GISL)
Annals of Oncology, 17:4-676:682, 2006-05-03
535) Luminari S., Federico M.: Prognosis of follicular lymphomas.
Hematological Oncology, 24:64-72, 2006
536) Markman M., Federico M., Liu PY., Hannigan E., Alberts D.: Significance of early changes in the
serum CA-125 antigen leve 1 on overall survival in advanced ovarian cancer.
Gynecologic Oncology, 103:195-198, 2006
537) Marotta G., Frassoldati A., Zinzani P., Annino L., Brugiatelli M., Ambrosetti A., Lenoci M.,
Federico M., Foa R., Lauria F; the Italian Cooperative group for HCL (ICOHCL): Role of interferonalpha administration after 2-deoxycoformycin in the treatment of hairy cell leukemia patients.
European Journal of Haematology, 77-2:109-113, 2006
549) Agata S., Viel A., Della Puppa L., Cortesi L., Fersini G., Callegaro M., Dalla Palma M., Dolcetti R.,
24/5/14
Page 9 / 20
Curriculum Vitae
Massimo Federico
Federico M., Venuta S., Miolo G., D’Andrea E., Montagna M.: Prevalence of BRCA1 genomic
rearrangements in a large cohort of italian breast and breast/ovarian cancer families without
detectable BRCA1 and BRCA2 point mutations.
Genes, Chromosomes & Cancer, 45:791-797, 2006
550) Gobbi P.G., Levis A., Chisesi T., Pavone V., Federico M., Brugiatelli M., on behalf of the
Intergruppo Italiano Linfomi: Unlike ABVD and MOPPEBVCAD, Stanford V chemotherapy does not
tollerate the combination with a reduced and conditioned radiotherapy for the treatment of advanced
Hodgkin Lymphoma
The American Journal of Oncology Review, 5-6:356-359, 2006
552) Visco C., Nadali G., Vassilakopoulos TP., Bonfante V., Viviani S., Gianni AM., Federico M.,
Luminari S., Peethambaram P., Witzig TE., Pangalis G., Cabanillas F., Medeiros LJ., Sarris AH.,
Pizzolo G.: Very high levels of soluble CD30 recognize the patients with classical Hodgkin’s
lymphoma retaining a very poor prognosis.
European Journal of Haematology, 77:387-394, 2006
559) Cortesi L., Turchetti D., Marchi I., Fracca A., Canossi B., Battista R., Ruscelli S., Pecchi A.R.,
Torricelli P., Federico M.: Breast cancer screening in women at increased risk accordino to different
family histories: an update of the Modena Study Group experience.
BMC Cancer, 17:6-210, 2006
560) El Mistiri M., Verdecchia A.,Rashid I., El Sahli N., El Mangush M., Federico M.: Cancer incidence
in eastern Libya: the first report the Benghazi Cancer Registry, 2003.
Int. J. Cancer, 120:392-397, 2006
561) Luminari S., Federico M.: The role of anthracyclines in follicular lymphomas. (Editorial)
562) Zorzi M., Puliti D., Vettorazzi M., De Lisi V., Falcini F., Federico M., Ferretti S., Moffa I.F.,
Mangone L., Mano M.P., Naldoni C., Ponti A., Traina A., Tumino R., Paci E. for the IMPACT Working
Group: Mastectomy rates are decreasin in the era of service screening: a population-based study in
Italy (1997-2001)
British Journal of Cancer, 95:1265-1268, 2006-12-22
572) Merli F., Bertini M., Luminari S., Mozzana R., Botto B., Liberati A.M., Baldini L., Cabras G., Di Vito
F., Orsucci L., Naglieri E., Polimeno G., Marcheselli L., Pennese E., Vitolo U., Federico M., Gallo E.:
Long term results of a randomized study performed by Intergruppo Ialiano Linfomi comparing MiniCEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma.
573) Sardanelli F., Podo F., D’Agnolo G., Verdecchia A., Santaquilani M., Musumeci R., Trecate G.,
Manoukian S., Morassut S., de Giacomi C., Federico M., Cortesi L., Concione S., Cirillo S., Marra V.,
for the High Brest Cancer Risk Italian Trial (HIBCRIT): Multicenter comparative multimodality
surveillance of women at genetic-familial risk for breast cancer (HIBCRIT study): interim results.
Radiology, 242-3:698-715, 2007
579) Cheson B.D., Pfistner B., Juweid M.E., Gascoyne R.D., Specht L., Horning S.J., Coiffier B.,
Fisher R.I., Hagenbeck A., Zucca E., Rosen S.T., Stroobants S., Lister A., Hoppe R.T., Dreyling M.,
Tobinai K., Vose J.M., Connors J.M., Federico M., Diehl V.: Revised response criteria for malignant
lymphoma.
Journal of Clinical Oncology, 25-5:579-586, 2007
580) Sacchi S., Pozzi S., Marcheselli FR., Federico M., Tucci A., Merli F., Orsucci L., Liberati M.,
Vallisa D., Brugiatelli M., on behalf of the Italian Lymphoma Study Group (GISL): Rituximab in
combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent
follicular lymphoma.
Cancer, 110:1-121:128, 2007
582) Federico M., Guglielmi C., Luminari S., Mammi C., Marcheselli L., Granelli U., Maiorana A., Merli
F., Bellei M., Pozzi S., Stelitano C., Lazzaro A., Gobbi G.P., Baldini L., Bergantini S., Fregoni V.,
Brugiatelli M.: Prognostic relevance of serum beta-2 microglobulin in patients with follicular lymphoma
treated with anthracycline containing regimens; a GISL study
Haematologica, 92-11:1482-1488,2007
586) Rashid I., Marcheselli L., Federico M.: Estimating survival in newly diagnosed cancer patients:
Use of computer simulations to evaluate performances of different approaches in a wide range of
scenarios.
24/5/14
Page 10 / 20
Curriculum Vitae
Massimo Federico
Statistics in Medicine,27:2145-2158,2008
590) Dal Maso L., Lise M., Zambon P., Crocetti E., Serraino D., Ricceri F., Vercelli M., De Lisi V.,
Tagliabue G., Federico M., Falcini F., Cassetti T., Donato A., Fusco M., Budroni M., Ferretti S., Tumino
R., Piffer S., Bellù F., Mangone L., Giacomin A., Vitarelli S., Franceschi S.: Incidence of primary liver
cancer in Italy between 1988 and 2002: an age-period-cohort analysis
European Journal of Cancer, 44(2):285-292,2008
591) Luminari S., Cesaretti M., Rashid I., Mammi C., Montanini A., Barbolini E., Bellei M., Pennese E.,
Sirotti A.M., Marcheselli L., Partesotti G., Bari A., Maiorana A., Bonacorsi G., Federico M.: Incidence,
clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer
registry in northern Italy.
Hematological Oncology, 25:189-197,2007
592) Goldaniga M, Ferrario A, Cortelazzo S, Guffanti A, Pavone E, Ambrosetti A, Marcheselli L, Rossi
F, Luminari S, Rossi A, Cro L, Federico M, Lambertenghi Deliliers G, Baldini L. : A multicenter
retrospective clinical study of CD5/CD10-negative chronic B cell leukemias.
Am J Hematol. 2008 May;83(5):349-54
593) Pavone V, Ricardi U, Luminari S, Gobbi P, Federico M, Baldini L, Iannitto E, Ucci G, Marcheselli
L, Orsucci L, Angelucci E, Liberati M, Gavarotti P, Levis A; Intergruppo Italiano Linfomi (IIL).: ABVD
plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma:
results from an Intergruppo Italiano Linfomi randomized study.
Ann Oncol. 2008 Apr;19(4):763-8.
598) Sacchi S., Marcheselli L., Bari A., Marcheselli R., Pozzi S., Gobbi PG:, Angrilli F., Brugiatelli M.,
Musto P., Federico M.: Second malignancies after treatment of diffuse large B-cell non-Hodgkin’s
lymphoma: a GISL cohort study.
Haematologica, 2008 Sep;93(9):1335-42. Epub 2008 Aug 12.
599) Puliti D., Miccinesi G., Collina N., De Lisi V., Federico M., Ferretti S., Finarelli AC., Foca F.,
Mangone L., Naldoni C., Putrella M., Ponti A., Segnan N., Sigona A., Zarcone M., Zorzi M., Zappa M.,
Paci E., IMPACT Working Group: Effectiveness of service screening: a case-control study to assess
breast cancer mortality reduction.
Br. J. Cancer, 99(3):423-7,2008
600) Neri A., Marmiroli S., Tassone P., Lombardi L., Nobili L., Verdelli D., Civallero M., Cosenza M.,
Bertacchini J., Federico M., De Pol A., Deliliers GL., Sacchi S.: The oral protein-kinase C beta inhibitor
enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and
induces apoptosis in multiple myeloma cell lines.
Leukemia & Lymphoma, 49(7):1374-83,2008
604) Federico M., Luminari S., Iannitto E., Polimeno G., Marcheselli L., Montanini A., La Sala A., Merli
F., Stelitano C., Pozzi S., Scalone R., Di Renzo N., Musto P., Baldini L., Cervetti G., Angrilli F., Mazza
P., Brugiatelli M., Gobbi P.G.: ABVD compared with BEACOPP compared with CEC for the initial
treatment of patients with advanced Hodgkin’s Lymphoma: results from the HD2000 Gruppo Italiano
per lo Studio dei Linfomi Trial
J Clin Oncol (ISSN 0732-183X) 27:5-805:11, 2009
605) Dal Maso L., Polesel J., Serraino D., Lise M., Piselli P., Falcini F., Russo A., Intrieri T., Vercelli M.,
Zambon P., Tagliabue G., Zanetti R., Federico M., Limina RM., Mangone L., De Lisi V., Stracci F.,
Ferretti S., Piffer S., Budroni M., Donato A., Giacomin A., Bellù F., Fusco M., Madeddu A., Vitarelli S.,
Tessandori R., Tumino R., Suligoi B., Frances hi S. for the Cancer and AIDS Registries Linkage
(CARL) Study: Pattern of cancer risk in persons with AIDS in Italy inthe HAART era.
British Journal of Cancer, 100:840-847,2009
606) Gobbi G.P., Valentino F., Da nova M., Morabito F., Rovati B., Mammi C., Gentile M., Merli F.,
Stelitano C., Luminari S., Quintana G., Iannitto E., Brugiatelli M., Federico M.: Bone marrow stem cell
damage after three different chemotherapy regimens for advanced Hodgkin’s lymphoma.
Oncology Reports, 21:1029-1035,2009-04-21
607) Carella A.M., Bellei M., Brice P., Gisselbrecht C., Visani G., Colombat P., Fabbiano F., Donelli A.,
Luminari S., Feugier P., Browett P., Hagberg H., Federico M.: High-dose therapy and autologous stem
cell transplantation versus conventional therapy for patients with advanced Hodgkin’s lymphoma
responding to front-line therapy: long term results.
Haematologica, 94(1).146-148,2009
608) Iannitto E., Minardi V., Gobbi P.G., Calvaruso G., Tripodo C., Marcheselli L., Luminari S., Merli F.,
24/5/14
Page 11 / 20
Curriculum Vitae
Massimo Federico
Baldini L., Stelitano C., Callea V., Petrini M., Angrilli F., Quarta G., Vallisa D., Molica s., Liardo E.,
Polimeno G., Brugiatelli M., Federico M.: Response-guided ABVD chemotherapy plus involved-field
radiotherapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era:
a Gruppo Italiano Studio Linfomi (GISL) prospective trial.
Clinical Lymphoma & Myeloma, 9(2):138-144,2009
613) Federico M., Bellei M., Marcheselli L., Luminari S., Lopez-Guillermo A., Vitolo U., Pro B., Pileri S.,
Pulsoni A., Soubeyran P., Cortelazzo S., Martinelli G., Martelli M., Rigacci L., Arcaini L., Di Raimondo
F., Merli F., Sabattini E., McLaughlin P., Solal-Céligny P.: Follicular Lymphoma International Prognostic
Index 2: a new prognostic index for follicular lymphoma developed by the International Follicular
Lymphoma Prognostic Factor Project.
Journal of Clinical Oncology, 1:9-4555:4562, 2009
617) Pecorari L., Marin O., Silvestri C., Candini O., Rossi E., Guerzoni C., Cattelani S., Mariani S.A.,
Corradini F., Ferrari-Amorotti G., Cortesi L., Bussolari R., Raschellà G., Federico M., Calabretta B.:
Elongation factor I alpha interacts with phospho-Akt in breast cancer cells and regulates their
proliferation, survival and motility.
Molecular Cancer, 8-58, 2009
618) Luminari S., Cesaretti M., Marcheselli L., Rashid I., Madrigali S., Maiorana A., Federico M.:
Decreasing incidence of gastric MALT lymphomas in the era of anti-Helicobacter pilori interventions:
results from a population-based study on extranodal marginal zone lymphomas
Annals of Oncology (ISSN 0923-7534) 1:4-855:859, 2009
I.F. 4,93
619) Cortesi L., Barchetti A., De Matteis E., Rossi E., Della Casa L., Marcheselli L., Tazzioli G.,
Lazzaretti M.G., Ficarra G., Federico M., Iannone A.: Identification of protein clusters predictive of
response to chemotherapy in breast cancer patients
Journal of Proteome Research (ISSN 1535-3893) 8:11-4916:33, 2009
I.F. 5,68
624) Meignan M., Itti E., Bardet S., Lumbroso J., Edeline V., Oliver P., Borghi TV., Reman O., Karcher
G., Mundler O., Mounier N., Ricci R., Federico M., Raemaekers J., Andrè M.: Development and
application of a real-time on-line blinded independent central review of interim PET scans to determine
treatment allocation in lymphoma trials
Journal of Clinical Oncology (ISSN 0732-183X) 27:16-2739:2741, 2009
I.F. 15,48
626) Luminari S., Montanini A., Caballero D., Bologna S., Notter M., Dyer M.J.S., Chiappella A.,
Briones J., Petrini M., Barbato A., Kayitalire L., Federico M.: Nonpegylated liposomal doxorubicin
(Myocet) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma
(DLBCL): results from the phase II EURO 18 trial
I.F. 4,93
627) Cortesi L., De Matteis E., Rashid I., Cirilli C., Proietto M., Rivasi F., Federico M.: Distribution of
second primari malignancies suggest a bidirectional effect between breast and endometrial cancer. A
population-based study
International Journal of Gynecological Cancer (ISSN 1048-891X) 19:8-1358:1363,2009
I.F. 1,93
628) Gobbi P.G., Rosti V., Valentino F., Bonetti E., Merli F., Stelitano C., Dondi A., Quarta G., Falorio
S., Federico M.: The early- and intermediate- term toxicity to primitive hematopoietic progenitor cells of
three chemotherapy regimens for advanced Hodgkin lymphoma
Clinical Lymphoma & Myeloma (ISSN 1557-9190) 9:6-425:429, 2009
I.F. 1,59
631) Molica S., Di Raimondo F., Cutrona G., Fabris S., Mauro F., Brugiatelli M., Baldini L., Musto P.,
Sacchi S., Cortelezzi A., Foà R., Neri A., Federico M., Ferrarini M., Morabito F., on behalf of Gruppo
Italiano Studio Linfomi (GISL): Clinical categories identified by a new prognostic index reflect biological
characteristics of patients in early chronic lymphocytic leukemia: The Gruppo Italiano Studi Linfomi
(GISL) experience
Leukemia Research (ISSN 0145-2126) 34:8-217:218, 2009
I.F. 2,39
24/5/14
Page 12 / 20
Curriculum Vitae
Massimo Federico
632) Allemani C., Storm H., Voogd A.C., Holli K., Izarzugaza I., Torrella-Ramos A., Bielska-Lasota M.,
Aareleid T., Ardanaz E., Colonna M., Crocetti E., Danzon A., Federico M., Garau I., Grosclaude P.,
Hèdelin G., Martinez-Garcia C., Peignaux K., Plesko I., Primic-Zakelj M., Rachtan J., Tagliabue G.,
Tumino R., Traina A., Tryggvadottir L., Vercelli M., Sant M.: Variation in “Standard care” for breast
cancer across Europe: a EUROCARE-3 high resolution study
European Journal of Cance (ISSN 0959-8049) 46:9-1528:1536, 2009
I.F. 4,47
633) Barrington S.F., Qian W., Somer E.J., Franceschetto A., Bagni B., Brun E., Almquist H., Loft A.,
Hojgaard L., Federico M., Gallamini A., Smith P., Johnson P., Radford J., O’Doherty M.J.:
Concordance between four European centre of PET reporting criteria designed for use in multicentre
trials in Hodgkin lymphoma
European Journal of Nuclear Medicine and Molecular Imaging (ISSN 1619-7070) 37:10-1824:1833,
2010
I.F. 4,53
634) Mannina D., Luminari S., Dondi A., Polimeno G., Baldini L., Stelitano C., Merli F., Dell’Olio M.,
Gobbi P.G., Giglio G., Barbolini E., Brugiatelli M., Federico M.: Long term outcome of patients with
localized aggressive non-Hodgkin lymphoma treated with PROMECE-CYTABOM plus involved-field
radiation therapy: a study by the Gruppo Italiano Studio Linfomi
Leukemia & Lymphoma (ISSN 1042-8194) 51:3-422:429, 2010
I.F. 2,49
635) Cortesi L., Masini C., Cirilli C., Medici V., Marchi I., Cavazzini G., Pasini G., Turchetti D., Federico
M.: Favourable ten-year overall survival in a Caucasian population with high probability of hereditary
breast cancer.
BMC Cancer (ISSN 1471-2407) 10:90, 2010
I.F. 2,74
636) Sardanelli F., Boetes B., Decker T., Federico M., Gilbert F.J., Helbich T., Heywang-Kobrunner
S.H., Kaiser W.A., Kerin M.J., Mansel R.E., Marotti L., Martincich L., Mauriac L., Meijers-Heijboer H.,
Orecchia R., Panizza P., Ponti A., Purushotham A.D., Regitnig P., Rosselli Del Turco M., Thibaukt F.,
Wilson R.: Magnetic resonance imaging of the breast: recommendations from the EUSOMA working
group
European Journal of Cancer (ISSN 0959-8049) 46:8-1296:1316, 2010
I.F. 4,12
637) El Mistiri M., Pirani M., El Sahli N., El Mangoush M., Attia A., Shembesh R., Habel S., El Homry
F., Hamad S., Federico M.: Cancer profile in Eastern Libya: incidence and mortality in the year 2004
I.F. 5,64
638) Federico M., Pirani M., Rashid I., Caranci N., Birilli C.: Cancer incidence in people with residential
exposure to a municipal waste incinerator: an ecological study in Modena (Italy), 1991-2005
Waste Management (ISSN 0956-053X) 30:7-1362:1370, 2010
I.F. 2,43
639) Di Renzo N., Montanini A., Mannina D., Dondi A., Muci S., Mancuso S., De Polis M.R., Plati C.,
Stelitano C., Patti C., Olivieri A., Liardo E., Buda G., Cantaffa R., Federico M.: Single-dose
Palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with
aggressive non-Hodgkin’s lymphoma receiving moderately emetogenic chemotherapy containing
steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL)
Support Care Cancer (ISSN 0941-4355) 19:10-1505:10, 2011
I.F. 2,08
640) Ferrario A., Merli F., Luminari S., Stelitano C., Mannina D., Russo M., Mazza P., Marcheselli L.,
Goldaniga M.,C., Federico M., Baldini L.: Phase II Fludarabine and Cyclophosphamide for the
treatment of indolent cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano
per lo Studio dei Linfomi
Annals of Hematology (ISSN 0939-5555) 90:3-323:30, 2011
I.F. 2,91
641) Mian M., Marcheselli L., Luminari S., Federico M., Cantonetti M., Sarris A.H., Rossi A., Rambaldi
A., Frontani M., Devizzi L., Gianni A.M., Busetto M., Berti E., Martinelli G., Tsang R.W., Ferreri A.J.M.,
24/5/14
Page 13 / 20
Curriculum Vitae
Massimo Federico
Pinotti G., Pugliani E., Zucca E., Cortelazzo S.: CLIPI: a new prognostic index for indolent cutaneos B
cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11)
Annals of Hematology (ISSN 0939-5555) 90:4-401:8, 2011
I.F. 2,91
649) Sardanelli F., Podo F., Santoro F., Manoukian S., Bergonzi S., Trecate G., Vergnaghi D., Federico
M., Cortesi L., Corcione S., Morassut S., Di Maggio C., Cilotti A., Martincich L., Calabrese M., Zuiani
C., Preda L., Bonanni B., Carbonaro LA., Contegiacomo A., Panizza P., Di Cesare E., Savarese A.,
Crecco M., Turchetti D., Tonutti M., Belli P., Maschio AD.: Multicenter surveillance of women at high
genetic breast cancer risk using mammography, ultrasonography, and contrast-enhanced magnetic
resonance imaging (the high breast cancer risk italian 1 study): final results High Breast Cancer Risk
Italian 1 (HIBCRIT-1) Study,
Invest Radiol (ISSN 0020-9996) 46:2-94:105, 2011
I.F. 4,85
650) Weisenburger DD., Savage KJ., Harris NL., Gascoyne RD., Jaffe ES., Maclennan KA., Rüdiger
T., Pileri S., Nakamura S., Nathwani B., Campo E., Berger F., Coiffier B., Kim WS., Holte H., Federico
M., Au WY., Tobinai K., Armitage JO., Vose JM.: Peripheral T-cell lymphoma, not otherwise specified:
a report of 340 cases from the International Peripheral T-cell Lymphoma Project
Blood (ISSN 0006-4971) 117:12-3402-3408, 2011
I.F. 10,55
651) Pirani M., Marcheselli R., Marcheselli L., Bari A., Federico M., Sacchi S.: Risk for second
malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis
Ann Oncol (ISSN 0923-7534) 22:8-1845:1858, 2011
I.F. 5,64
652) Mian M., Gaidano G., Conconi A., Tsang R., Gospodarowicz MK., Rambaldi A., Rossi A., Oldani
E., Federico M., Luminari S., Bellei M., Pogliani EM., Rossini F., Cabrera ME., Martelli M., LopezGuillermo A., Busetto M., Cavalli F., Zucca E., Cortelazzo S. : High response rate and improvement of
long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse
large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano
Linfomi study
I.F. 2,49
653) Delabie J., Holte H., Vose JM., Ullrich F., Jaffe ES., Savage KJ., Connors JM., Rimsza L., Harris
NL., Muller-Hermelink K., Rudiger T., Coiffier B., Gascoyne RD., Berger F., Tobinai K., Au WY., Liang
R., Montserrat E., Hochberg EP., Pileri S., Federico M., Nathwani B., Armitage JO., Weisenburger
DD.: Enteropathy-associated T-cell lymphoma: clinical and histological findings from the International
Peripheral T-Cell Lymphoma Project
Blood (ISSN 0006-4971) 118:1-148:155, 2011
I.F. 10,55
654) Gobbi PG., Federico M.: What has happened to VBM (vinblastine, bleomycin, and methotrexate)
chemotherapy for early-stage Hodgkin lymphoma?
Critical Reviews in Oncology Hematology (ISSN 1040-8428) 82:1-18:24, 2011
I.F. 5,26
656) Gobbi PG., Valentino F., Bassi E., Coriani C., Merli F., Bonfante V., Marchianò A., Gallamini A.,
Bolis S., Stelitano C., Levis A., Federico M., Angrilli F., Di Giulio G., Corazza GR.: Chemoresistance as
a function of the pretherapy tumor burden and the chemotherapy regimen administered: differences
observed with 2 current chemotherapy regimens for advanced Hodgkin Lymphoma
Clin Lymphoma Myeloma Leuk (ISSN 2152-2650) 11:5-396:402, 2011
I.F. 1,98
657) Cortesi L., Rossi E., Della Casa L., Barchetti A., Nicoli A., Piana S., Abrate M., La Sala GB.,
Federico M., Iannone A.: Protein expression patterns associated with advanced stage ovarian cancer
Electrophoresis (ISSN 0173-0835) 32:15-1992:-2003, 2011
I.F. 3,56
658) Luminari S., Cesaretti M., Tomasello C., Guida A., Bagni B., Merli F., Postiglione r., Mangone L.,
Versari A., Re F., De Lisi V., Ruffini L., Ferretti S., Cuneo A., Federico M.: Use of 2-[18F]fluoro-2deoxy-D-glucose positron emission tomography in patients with Hodgkin lymphoma in daily practice: a
24/5/14
Page 14 / 20
Curriculum Vitae
Massimo Federico
population-based study from Northern Italy
I.F. 2,49
659) Maura F., Cutrona G., Fabris S., Colombo M., Tuana G., Agnelli L., Matis S., Lionetti M., Gentile
M., Recchia A.G., Di Raimondo F., Musolino C., Ilariucci F., Di Renzo N., Pesce E., Molica S.,
Federico M., Cortelezzi A., Morabito F., Ferrarini M., Neri A.: Relevance of stereotyped B-cell
receptors in the context of the molecular, cytogenetic and clinical features of chronic lymphocytic
leukemia
PLoS One (ISSN 1932-6203) 6:8-e24313, 2011
I.F. 4,4
660) Chisesi T., Bellei M., Luminari S., Montanini A., Marcheselli L., Levis A., Gobbi P.G., Vitolo U.,
Stelitano C., Pavone V., Merli F., Liberati M., Baldini L., Bordonaro R., Pesce E.A., Federico M.: Longterm follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versusu
MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin’s lymphoma: a study
from the Intergruppo Italiano Linfomi.
I.F. 18,97
664) Merli F., Luminari S., Rossi G., Mammi C., Marcheselli L., Tucci A., Ilariucci F., Chiappella A.,
Musso M., Di Rocco A., Stelitano C., Alvarez I., Baldini L., Mazza P., Salvi F., Arcari A., Fragasso A.,
Gobbi P.G., Liberati A.M., Federico M.: R-CHOP vs R-miniCEOP for the initial treatment of elderly “fit”
patients with diffuse large B-cell lymphoma. Results from the ANZINTER3 trial of the Intergruppo
Italiano Linfomi (IIL)
I.F. 2,30
665) Morabito F., Hohaus S., Mammi C.,Marcheselli L., Gentile M., Merli F., Montanini A., Stelitano C.,
La Salal A., Scalone R., Voso M.T., Luminari S., Iannitto E., Gobbi P.G., Federico M.: Role of
Glutathione-S-Transferase (GST) polymorphisms in patients with advanced Hodgkin Lymphoma:
results from the HD2000 GISL Trial
I.F. 2,30
666) Merli F., Luminari S., Ilariucci F., Petrini M., Visco C., Ambrosetti A., Stelitano C., Caracciolo F., Di
Renzo N., Angrilli F., Carella A.M., Capodanno I., Barbolini E., Galimberti S., Federico M.: Rituximab
plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial tretment of
patients with mantle cell lymphoma: a multicentre trial from Gruppo Italiano Studio Linfomi.
Br J Haematol (ISSN 1365-2141 ) 156:3-346:353, 2012
I.F. 4,9
667) Joensuu H., Vehtari A., Riihimaki J., Nishida T., Steigen S.E., Brabec P., Plank L., Nilsson B.,
Cirilli C., Braconi C., Magnusson M.K., Linke Z., Sufliarsky J., Federico M., Jonasson J.G., Dei Tos
A.P., Rutkowski P.,: Risk of recurrence of gastrointestinal stromal tumor after surgery: an analysis of
pooled population-based cohorts.
Lancet Oncol (ISSN 1470-2045) 13:3-265:274, 2012
I.F. 17,7
668) Gobbi P.G., Bassi E., Bergonzi M., Merli F., Coriani C., Iannitto E., Luminari S., Polimeno G.,
Federico M.:Tumor burden predicts treatment resistance in patients with early unfavourable or
advanced Hodgkin lymphoma treated with ABVD and radiotherapy.
Hematological Oncology (ISSN 0278-0232) 30:4-194:199, 2012
I.F. 2,2
674) Cortesi L, Proietto M., Cirilli C., Tazzioli G., Andreotti A., Federico M.: Prognosis and treatment of
micrometastatic breast cancer sentinel lymph node: a population-based study.
J Surg Oncol (ISSN 0022-4790) 106:4-399:404, 2012
I.F. 2,42
675) Cortesi L., De Nicolo A., Medici V., Marino M., Turchetti D., Pradella LM., Rossi G., Parisini E.,
Federico M.: Collective evidence supports neutrality of BRCA1 v1687i, a novel sequence variant in
the conserved THV motif of the first BRCT repeat.
24/5/14
Page 15 / 20
Curriculum Vitae
Massimo Federico
Breast Cancer Res Treat (ISSN 0167-6806) 134:1-435:441, 2012
I.F. 4,85
676) Federico M., Rudiger T., Bellei M., Nathwani BN., Luminari S., Coiffier B., Harris NL., Jaffe E.,
Pileri S., Savane KJ., Weisenburger DD., Armitage JO., Mounier N., Vose Jm.: Clinicopathologic
characteristics of angioimmunoblastics T-cell lymphoma (AITL): analysis of 243 cases from the
International Peripheral T-cell Lymphoma Project
I.F. 18,97
677) Solal-Céligny P., Bellei M., Marcheselli L., Pesce,E.A., Pileri S., McLaughlin P., Luminari S., Pro
B., Montoto S., Ferreri A.J.M., Deconinck E., Milpied N., Gordon L.I., Federico M.: Watchful Waiting In
Low-Tumor Burden Follicular Lymphoma In The Rituximab Era. Results Of A F2 Observational
Study
I.F. 18,97
679) Gobbi P.G., Bergonzi M., Bassi E., Merli F., Coriani C., Stelitano C., Iannitto E., Federico M.:
Tumor burden in Hodgkin’s lymphoma can be reliably estimated from a few staging parameters.
Oncology Reports (ISSN 1021-335X) 28:3-815:820, 2012
I.F. 1,83
681) Carella AM; De Souza C., Luminari S., Marcheselli L., Chiappella A., Di Rocco A., Cesaretti M.,
Rossi A., Rigacci L., Gaidano G., Merli F., Spina M., Stelitano C., Hohaus S., Barbui A., Puccini B.,
Mirando E., Guida A., Federico M.: Prognostic role of gender in diffuse large B-cell lymphoma treated
with Rituximab containing regimens: a FIL/GEMOH retrospective study.
I.F. 2,30
682) Sant M., Minicozzi P., Allemani C., Cirilli C., Federico M., Capocaccia R., Budroni M., Candela P.,
Crocetti E., Falcini F., Ferretti S., Fusco M., Giacomin A., La Rosa F., Mangone L., Natali M., Leon
MP., Traina A., Tumino R., Zambon P.: Regional inequalities in cancer care persist in Italy and can
influence survival.
Cancer Epidemiology (ISSN 1877-7821) 36:6-541:547, 2012
I.F. 2,01
683) Mian M., Ferreri AJ., Rossi A., Conconi A., Tsang R., Gospodarowicz MK., Oldani E., Federico
M., Luminari S., Pogliani EM., Rossigni F., Cabrera ME., Martelli M., Gutierrez-Garcia G., Busetto M.,
Cavalli F., Zucca E., Rambaldi A., Cortelazzo S., on behalf of the International Extranodal Lymphoma
Study Group (I.E.L.S.G.): The role of radiotherapy in patients with early-stage diffuse large B-cell
lymphomas of the Waldeyer’s ring in remission after anthracycline-containing chemotherapy.
I.F. 2,30
685) Cortesi L., Marcheselli L., Guarneri V., Cirilli C., Braghiroli B., Toss A., Sant M., Ficarra G., Conte
P.F., Federico M.: Tumor size, node status, grading, HER2 and estrogen receptor status still retain a
strong value in patients with operable breast cancer diagnosed in recent years.
International Journal of Cancer (ISSN 0020-7136) 132:2-E58:65, 2013
I.F. 5,44
687) Falorio S., Biasoli I., Luminari S., Quintana G., Musso M., Dell’Olio M., Specchia M.R., Di Renzo
N., Cesaretti M., Buda G., Vallisa D., Mannina D., Andriani A., Chiattone C.S., Delamain M.T., De
Souza C.A., Spector N., Angrilli F., Federico M.: Risk factor for impaired gonadal function in female
Hodgkin lymphoma survivors: final analysis of a retrospective multicenter joint study from italian and
brazilian institutions.
Hematological Oncology (ISSN 0278-0232) 31:2-332:338, 2012
I.F. 2,03
688) Ghielmini M., Vitolo U., Kimby E., Montoto S., Walewski J., Pfreundschuh M., Federico M.,
Hoskin P., McNamara C., Caligaris-Cappio F., Stilgenbauer S., Marcus R., Trneny M., Dreger P.,
Montserrat E., Dreyling M., on behalf of the Panel Members of the 1st ESMO Consensus Conference
on Malignant Lymphoma:
ESMO guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell
24/5/14
Page 16 / 20
Curriculum Vitae
Massimo Federico
lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).
I.F. 6,42
690) Molica S., Giannarelli D., Gentile M., Cutrona G., Di Renzo N., Di Raimondo F., Neri A., Federico
M., Ferrarini M., Morabito F.: External validation on a prospective basis of a nomogram for predicting
the time to first treatment in patients with chronic lymphocytic leukemia.
Cancer (ISSN 0008-543X) 119:6-1177:1185, 2013
I.F. 4,77
693) Bari A., Tadmor T., Sacchi S., Marcheselli L., Liardo E.V., Pozzi S., Luminari S., Baldini L.,
Marmiroli S., Federico M., Polliack A.: Monocytosis has adverse prognostic significance and impacts
survival in patients with T-cell lymphomas
Leukemia Research (ISNN 0145-2126) 37:6-619:623, 2013
I.F. 2,92
694) Molica S., Giannarelli D., Gentile M., Cutrona G., Di Renzo N., Di Raimondo F., Neri A., Federico
M., Ferrarini M., Morabito F.: The utility of two prognostic models for predicting time to first treatment in
early chronic lymphocytic leukemia patients: results of a comparative analysis
Leukemia Research (ISNN 0145-2126) 37:8-943:947, 2013
I.F. 2,92
695) Merli F., Luminari S., Rossi G., Mammi C., Marcheselli L., Ferrari A., Spina M., Tucci A., Stelitano
C., Capodanno I., Fragasso A., Baldini L., Bottelli C., Montechiarello E., Fogazzi S., Lamorgesse C.,
Cavalli L., Federico M.: Outcome of frail of elderly patients with diffuse large B-cell lymphoma (DLBCL)
prospectively identified by comprehensive geriatric assessment (CGA). Results from a study of the
Fondazione Italiana Linfomi (FIL).
Leukemia & Lymphoma (ISSN 1042-8194), 55:1-38:43, 2014
I.F. 2,30
696) Federico M., Luminari S., Dondi A., Tucci A., Vitolo U., Rigacci L., Di Raimondo F., Carella A.M.,
Pulsoni A., Merli F., Arcaini L., Angrilli F., Stelitano C., Gaidano G., Dell’Olio M., Marcheselli L., Franco
V., Galimberti S., Sacchi S., Brugiatelli M .: R-CVP versus R-CHOP versus R-FM for the initial
treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted
by the Fondazione Italiana Linfomi.
I.F. 18,97
697) Gentile M., Cutrona G., Fabris S., Pesce E.A., Baldini L., Di Raimondo F., Musolino C., Di Tonno
P., Di Renzo N., Molica S., Brugiatelli M., Ilariucci F., Zupo S., Matias S., Maura F., Vigna E., Angrilli F.,
Recchia A.G., Quarta G., Iannitto E., Fragasso A., Musto P., Spriano M., Vincelli I., Vallisa D.,
Cortelezzi A., Mauro F.R., Foà R., Federico M., Neri A., Ferrarini M., Morabito F.: Total body computer
tomography scan in the initial work-up of binet stage a chronic lymphocytic leukemia patients: results
of the prospective, multicenter o-cll1-gisl study
American Journal of Hematology (ISNN 0361-8609) 88:7-539:544, 2013
I.F. 4,13
698) Luminari S., Biasoli I., Arcaini L., Versari A., Rusconi C., Merli F., Spina M., Ferreri A.J., Zinzani
P.L., Gallamini A., Mastronardi S., Boccomini C., Gaidano G., D’Arco A.M., Di Raimondo F., Carella
A.M., Santoro A., Musto P., Federico M.: The use of FDG-PET in the initial staging of 142 patients with
follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione
Italiana Linfomi
Annals of Oncology (ISSN 0923-7534) 24:8-2108-2112, 2013
I.F. 6,42
699) Toss A., De Matteis E., Rossi E., Della Casa L., Iannone A., Federico M., Cortesi L.: Ovarian
cancer: can proteomics give new insights for therapy and diagnosis?
International Journal of Molecolar Sciences (ISNN 1661-6596) 14:4-8271:8290, 2013
I.F. 2,59
700) Bella F., Minicozzi P., Giacomin A., Crocetti E., Federico M., Ponz de Leon M., Fusco M., Tumino
R., Mangone L., Giuliani O., Budroni M., Sant M.: Impact of diabetes on overall and cancer-specific
mortalità in colorectal cancer patients.
24/5/14
Page 17 / 20
Curriculum Vitae
Massimo Federico
Journal of Cancer Research and Clinical Oncology (ISNN 0171-5216) 139:8-1303:1310, 2013
I.F. 2,55
707) Zucchetto A., Ronco G., Rossi P.G., Zappa M., Ferretti S., Franzo A., Falcini F., Visioli G.B.,
Zanetti R., Biavati P., La Rosa F., Baracco S., Federico M., Campari C., De Togni A., Piffer S.,
Pannozzo F.,
Fusco M., Michiara M., Castaing M., Seghini P., Tisano F., Serraino D.: Screening patterns within
organized programs and survival of italian women with invasive cervical cancer
Preventive Medicine (ISNN 0091-7435) 57:3-220:226, 2013
I.F. 3,49
711) Piccaluga P.P., Fuligni F., De Leo A., Bertuzzi C., Rossi M., Bacci F., Sabattini E., Agostinelli C.,
Gazzola A., Laginestra M.A., Mannu C., Sapienza M.R., Hartmann S., Hansmann M.L., Piva R., Iqbal
J., Chan J.C., Weisenburger D., Vose J.M., Bellei M., Federico M., Inghirami G., Zinzani P.L., Pileri
S.A.: Molecular profiling improves classification and prognostication of nodal peripheral T-cell
lymphomas: results of a phase III diagnostic accuracy study
I.F. 18,97
712) Zaja F., Federico M., Vitolo U., Zinzani P.L.: Management of relapsed/refractory mantle cell
lymphoma: a review of current therapeutic strategies
Leukemia & Lymphoma (ISSN 1042-8194) 55:5-988.998, 2013
I.F. 2,30
713) Pozzi S.,. Marcheselli L., Bari A., Liardo E.V., Marcheselli R., Luminari S., Quaresima M., Cirilli
C., Ferri P., Federico M., Sacchi S.: Survival of multiple myeloma patients in the era of novel therapies
confirms the improvement in patients younger than 75 years: a population-based analysis
British Journal of Haematology (ISNN 0007-1048 ) 163:1-40:46, 2013
I.F. 4,94
714) Minicozzi P., Bella F., Toss A., Giacomin A., Fusco M., Zarcone M., Tumino R., Falcini F.,
Cesaraccio R., Candela G., La Rosa F., Federico M., Sant M.: Relative and disease-free survival for
breast cancer in relation to subtype: a population-based study
Journal of Cancer Research and Clinical Oncology (ISNN 0171-5216) 139:9-1569:1577, 2013
I.F. 2,91
715) Tadmor T., Bari A., Sacchi S., Marcheselli L., Liardo E.V., Avivi I., Beniamini N., Attias D., Pozzi
S., Cox M.C., Baldini L., Brugiatelli M., Federico M., Polliack A.: Monocyte count at diagnosis is a
prognostic parameter in diffuse large B-cell lymphoma: a large multicenter study involving 1191
patients, in the pre and post rituximab era
Haematologica (ISNN 0390-6078), 99:1-125:30, 2014
I.F. 5.93
716) Mian M., Capello D., Ventre M.B., Grazio D., Svaldi M., Rossi A., Tsang R., Gospodarowicz M.K.,
Oldani E., Federico M., Luminari S., Marcheselli L., Pogliani E.M., Rossigni F., Cabrera M.E., Martelli
M., Gutierrez-Garcia G., Busetto M., Visco C., Fiegl M., Rossi D., Gaidano G., Cavalli F., Zucca E.,
Rambaldi A., Cortelazzo S.: Early-stage diffuse large B cell lymphoma of the head and neck: clinicobiological characterization and 18 year follow-up of 488 patients (IESLG 23 study)
Annals of Hematology (ISSN 0939-5555), 2013
Published online August 20, 2013
I.F. 2,86
718) Colaci M., Giuggioli D., Vacchi C., Lumetti F., Iachetta F., Marcheselli L., Federico M., Ferri C.:
Breast cancer in systemic sclerosis: results of a cross-linkage of an Italian Rheumatologic Center and
a population-based Cancer Registry and review of the literature.
Autoimmunity Reviews (ISNN 1568-9972) 13:2-132:137, 2013
I.F. 7,97
719) Pashaj E., Cortesi L., Proietto M., Bonacorsi G., Liardo E., Federico M.: A case of skeletal and
bone marrow metastases from breast cancer treated with eribulin mesylate.
Future Oncology (ISNN1479-6694) 9:10-1437:1442, 2013
I.F. 3,20
24/5/14
Page 18 / 20
Curriculum Vitae
Massimo Federico
721) Federico M., Bellei M., Cheson B.D.: BEACOPP or no BEACOPP
Lancet Oncol. (ISNN 1470-2045) 14:12-e487:e488, 2013
I.F. 14,47
724) Cortesi L., Razzaboni E., Toss A., De Matteis E., Marchi I., Medici V., Tazzioli G., Andreotti A., De
Santis G., Pignatti M., Federico M.: A rapid genetic counselling and testing in newly diagnosed breast
cancer is associated with high rate of risk-reducing mastectomy in BRCA1/2-positive italian women.
I.F. 6,42
725) Luminari S., Biasoli I., Versari A., Rattotti S., Battelli C., Rusconi C., Merli F., Spina M., Ferreri
A.J., Zinzani P.L., Gallamini A., Franceschetto A., Boccomini C., Franceschetti S., Salvi F., Raimondo
F.D., Carella A.M., Quaresima M., Balzarotti M., Musto P., Federico M.: The prognostic role of postinduction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the
Fondazione Italiana Linfomi (FIL).
Annali of Oncology (ISSN 0923-7534) 25:2-442:447, 2014
I.F. 6,42
726) Raemaekers J.M.M., Andrè M.P.E., Federico M., Girinsky T., Oumedaly R., Brusamolino E.,
Brice P., Fermè C., van der Maazen R., Gotti M., Bouabdallah R., Sebban C.J., Lievens Y., Re A.,
Stamatoullas A., Morschhauser F., Lugtenburg P.J., Abruzzese E., Olivier P., Casasnovas R.O., van
Imhoff G., Raveloarivahy T., Bellei M., van der Borght T., Bardet S., Versari A., Hutchings M., Meignan
M., Fortpied C.: Omitting radiotherapy in early positron emission tomography-negative stage I/II
Hodgkin lymphoma is associadet with an increased risk of early relapse: clinical results of the
preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 Trial
I.F. 18,97
727) Zinzani P.L., Federico M., Oliva S., Pinto A., Rigacci L., Specchia G., Tucci A., Vitolo U.: The
more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive
non-Hodsgkin lymphoma.
Leukemia & Lymphoma (ISSN 1042-8194), 2014
Published online March 24, 2014
I.F. 2,30
728) Gentile M., Cutrona G., Mosca L., Matis S., Fabris S., Lionetti M., Ilariucci F., Zupo S., Musolino
C., Levato L., Molica S., Di Raimondo F., Vincelli I., Di Renzo N., Pesce E.A., Angrilli F., Federico M.,
Neri A., Ferrarini M., Morabito F.: Prospective validation of a risk score based on biological markers for
predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: results of
the multicenter O-CLL 1-GISL study
American Journal of Hematology (ISNN 0361-8609), 2014
Published online April 8, 2014
I.F. 4,13
729) Biasoli I., Cesaretti M., Bellei M., Maiorana A., Bonacorsi G., Quaresima M., Salati M., Federico
M., Luminari S.: Dismal outcomem of t-call lymphoma patients failing first-line treatment: results of a
population-based study from the Modena Cancer Registry
Hematological Oncology (ISSN 0278-0232), 2014
Published online April 29, 2014
I.F. 2,03
730) Bari A., Tadmor T., Sacchi S., Marcheselli L., Cox C., Liardo E.V., Pozzi S., Beniamini N., Avivi I.,
Ferrari A., Baldini L., Falorio S., Gobbi P., Federico M., Polliack A.: Defining the best cut-off value for
lymphopenia in diffuse large B cell lymphoma treated with immuno-chemotherapy
British Journal of Haematology (ISNN 0007-1048 ), 2014
Published online May 3, 2014
I.F. 4,94
Projects
24/5/14
He was a member of the executive committee of the International Follicular Lymphoma Prognostic
Factor Project (FLIPI), launched in 2000 by Dr Philippe Solal-Celigny in Le Mans, France. In 2003, as
a further development of the FLIPI consortium, professor Federico launched the idea of prospective
Page 19 / 20
Curriculum Vitae
Massimo Federico
collect clinical and biological data to investigate prognosis in patients with FL. The FLIPI2 study was
commenced and collected more than 1,000 cases of FL in 2 years. The final results were published in
2009 on JCO.
Following the conclusion of the FLIPI2 study, a similar project was also proposed for T Cell
Lymphoma. Thus the T Cell Project was launched, allowing the collection of more than 1200 cases of
PTCL collected so far. The final results of this study will be presented once again in Lugano, at the
13th International Conference on Malignant Lymphoma scheduled for June 2015.
Memberships
- Italian Society of Haematology
- Italian Society of Medical Oncology
- Italian Society of Cancerology
- American Society of Clinical Oncology
- American Society of Hematology
- European Society of Medical Oncology
- International Association of Cancer Registry
Other Relevant Information
In 1994 Professor Federico launched a fundraising campaign to create a new cancer center in
Modena. The camapign was successful and in December 2001 the center opened to patients.
AWARDS
1989 "NATO Senior Fellowships" grant from CNR (Italian Council of Research)
1993 Grant from Italian Foundation for Cancer Research
1994 Grant from National Cancer Institute of Bethesda, Maryland
1995 Agreement as “Assistant Research Scientist” at University of Arizona
1999 “Terra del Sole” Award from Premio Barocco Committee, Gallipoli (LE)
2003 “Mediterraneo” Award, Gallipoli (LE)
2003 “Mancaversa in fiore” Award, Taviano (LE)
2006 Silver Plate from “Provincia di Salerno”
2007 Scientific Research Award, 2007 – AIL Salerno
2008 “La Lampada di Aladino” Award, Brugherio (MI)
2008 “La Torre” Award, Città di Racale (LE)
2009 “Modenese dell’anno”, Award Modena Qui, S.Cesario s/Panaro (MO)
2010 “Ottaviano 2010” Award, Taviano (LE)
2010 Guido Di Domenico, Award Cava dé Tirreni (SA)
2011 “Melvin Jones Fellow”, Lions Club Award, Taviano (LE)
2011 “Kallistos Award - a life for research” , Mancaversa-Taviano (LE)
2012 Premio 3° Memorial Dott. Renato Marzano, Racale (LE)
24/5/14
Page 20 / 20

Massimo Federico - EMA

Transcript

Documenti analoghi

scheda 13

poperfect!

IL MIO MIGLIORE AMICO

versione Pdf - Intersezioni

Marina De Iorio - Master Lighting Design

L`eredità di leo Lionni

ritmo volantino - Il Mondo che Verrà

Concerto del Primo Maggio: il fotoracconto